Elicio Therapeutics (Elicio Therapeutics) Ending Cash Position : $13.21 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Elicio Therapeutics Ending Cash Position?

Elicio Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $13.21 Mil.

Elicio Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 ($17.20 Mil) to Dec. 2023 ($14.30 Mil) and declined from Dec. 2023 ($14.30 Mil) to Mar. 2024 ($13.21 Mil).

Elicio Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($10.05 Mil) to Dec. 2022 ($8.41 Mil) but then increased from Dec. 2022 ($8.41 Mil) to Dec. 2023 ($14.30 Mil).

Elicio Therapeutics Ending Cash Position Historical Data

The historical data trend for Elicio Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elicio Therapeutics Ending Cash Position Chart

Elicio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

6.81

14.97

10.05

8.41

14.30

Elicio Therapeutics Quarterly Data
	Dec19	Mar20	Dec20	Mar21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial								10.30	22.36	17.20	14.30	13.21

Elicio Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Elicio Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	8.414	+	5.887
	=	14.30

Elicio Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	14.301	+	-1.095
	=	13.21

Elicio Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Elicio Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Elicio Therapeutics (Elicio Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Elicio Therapeutics Inc (NAS:ELTX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

9HA:Germany

Address

One Kendall Square, Building 1400 West, Suite 14303, Cambridge, MA, USA, 02139

Website

https://www.elicio.com

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.

Executives

Yekaterina Chudnovsky	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Robert R Ruffolo	director
Peter Demuth	officer: Chief Scientific Officer	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Assaf Segal	director	C/O ELICIO THERAPEUTICS, INC., 451 D STREET, 5TH FLOOR, SUITE 501, BOSTON MA 02210
Annette Matthies	officer: Chief Business Officer	ONE KENDALL SQUARE, BUILDING 1400 WEST, SUITE 14303, CAMBRIDGE MA 02139
Robert Connelly	director, officer: CEO, President and Director	1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Julian Adams	director	C/O GAMIDA CELL, 673 BOYLSTON STREET, 4TH FLOOR, BOSTON MA 02116
Christopher Haqq	officer: See Remarks	C/O ATARA BIOTHERAPEUTICS, INC., 3260 BAYSHORE BOULEVARD, BRISBANE CA 94005
Carol Gail Ashe	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Brian Piekos	officer: Chief Financial Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Karen J Wilson	director	C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Gilbert S Omenn	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Gregory S Curhan	officer: See Remarks	600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108
Itzhak Goldberg	officer: See Remarks	51 CHARLES LINDBERGH BLDV., UNIONDALE NY 11553
John F. Neylan	officer: See Remarks	750 LEXINGTON AVENUE, NEW YORK NY 10022